Handelsbanken Fonder AB Buys 2,900 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)

Handelsbanken Fonder AB increased its stake in Sage Therapeutics, Inc. (NASDAQ:SAGE) by 29.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 12,644 shares of the biopharmaceutical company’s stock after buying an additional 2,900 shares during the quarter. Handelsbanken Fonder AB’s holdings in Sage Therapeutics were worth $274,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in SAGE. Teacher Retirement System of Texas grew its holdings in Sage Therapeutics by 4.8% during the 3rd quarter. Teacher Retirement System of Texas now owns 15,278 shares of the biopharmaceutical company’s stock valued at $314,000 after buying an additional 698 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Sage Therapeutics by 95.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,531 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 748 shares during the period. CWM LLC lifted its stake in Sage Therapeutics by 274.2% in the 3rd quarter. CWM LLC now owns 1,205 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 883 shares in the last quarter. Inspire Investing LLC boosted its holdings in Sage Therapeutics by 8.4% in the 3rd quarter. Inspire Investing LLC now owns 15,049 shares of the biopharmaceutical company’s stock valued at $310,000 after purchasing an additional 1,169 shares during the period. Finally, Swiss National Bank grew its position in shares of Sage Therapeutics by 1.0% during the 3rd quarter. Swiss National Bank now owns 118,200 shares of the biopharmaceutical company’s stock valued at $2,433,000 after purchasing an additional 1,200 shares in the last quarter. 99.22% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on SAGE shares. Oppenheimer dropped their price objective on Sage Therapeutics from $25.00 to $17.00 and set a “market perform” rating for the company in a research note on Thursday, April 18th. HC Wainwright cut their price objective on Sage Therapeutics from $28.00 to $25.00 and set a “neutral” rating for the company in a report on Friday, April 26th. Wedbush reaffirmed a “neutral” rating and issued a $24.00 target price on shares of Sage Therapeutics in a research note on Wednesday, April 17th. Canaccord Genuity Group cut their price target on shares of Sage Therapeutics from $21.00 to $17.00 and set a “hold” rating for the company in a research note on Friday, April 26th. Finally, Scotiabank lowered their price objective on shares of Sage Therapeutics from $34.00 to $19.00 and set a “sector outperform” rating on the stock in a research report on Thursday, April 18th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $37.67.

Sage Therapeutics Trading Down 1.3 %

NASDAQ SAGE opened at $13.11 on Friday. The stock has a 50-day moving average of $17.85 and a 200-day moving average of $20.47. Sage Therapeutics, Inc. has a 1-year low of $10.92 and a 1-year high of $59.99. The firm has a market cap of $788.66 million, a PE ratio of -1.56 and a beta of 0.91.

Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.80) earnings per share for the quarter, missing the consensus estimate of ($1.63) by ($0.17). Sage Therapeutics had a negative net margin of 552.52% and a negative return on equity of 56.81%. The company had revenue of $7.90 million during the quarter, compared to the consensus estimate of $5.26 million. During the same quarter in the previous year, the firm posted ($2.46) EPS. The business’s revenue for the quarter was up 139.4% compared to the same quarter last year. As a group, equities research analysts forecast that Sage Therapeutics, Inc. will post -6.6 earnings per share for the current fiscal year.

Sage Therapeutics Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.